Analystreport

Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations